Tumor hypoxia as a driving force in genetic instability

Genome Integrity

Volumn 4, Issue 1, 2013, Pages

  Luoto, Kaisa R ^a   Kumareswaran, Ramya ^a,b   Bristow, Robert G ^a,b  

^a PRINCESS MARGARET HOSPITAL   (Canada)

^b UNIVERSITY OF TORONTO   (Canada)

Author keywords

DNA damage; DNA double strand breaks; DNA repair; Genetic instability; Hypoxia

Indexed keywords

ANTINEOPLASTIC AGENT; TH 302; UNCLASSIFIED DRUG;

CHROMOSOMAL INSTABILITY; DNA DAMAGE CHECKPOINT; DNA REPLICATION; DNA STRAND BREAKAGE; DRUG MECHANISM; DRUG TARGETING; EXCISION REPAIR; FANCONI ANEMIA; GENOMIC INSTABILITY; HUMAN; HYPOXIA; MICROSATELLITE INSTABILITY; MISMATCH REPAIR; NONHUMAN; PRIORITY JOURNAL; REVIEW; SIGNAL TRANSDUCTION; TRANSLATION REGULATION; TUMOR CELL; TUMOR HYPOXIA; TUMOR MICROENVIRONMENT;

EID: 84886004764     PISSN: None     EISSN: 20419414     Source Type: Journal    
DOI: 10.1186/2041-9414-4-5     Document Type: Review

References (144)

1. Vaupel P, Harrison L. Tumor hypoxia: causative factors, compensatory mechanisms, and cellular response. Oncologist 2004, 9(Suppl 5):4-9.
2. Hill RP, Bristow RG. The Scientific Basis of Radiotherapy. The Basic Science of Oncology 2005, 289-321. New York: McGraw-Hill Ltd, Tannock IF, Hill RP, Bristow RG, Harrington L.
3. Chan N, Koch CJ, Bristow RG. Tumor hypoxia as a modifier of DNA strand break and cross-link repair. Curr Mol Med 2009, 9:401-410. 10.2174/156652409788167050, 19519397.
4. Vaupel P, Mayer A. Hypoxia in cancer: significance and impact on clinical outcome. Cancer Metastasis Rev 2007, 26:225-239. 10.1007/s10555-007-9055-1, 17440684.
5. Ljungkvist AS, Bussink J, Kaanders JH, van der Kogel AJ. Dynamics of tumor hypoxia measured with bioreductive hypoxic cell markers. Radiat Res 2007, 167:127-145. 10.1667/RR0719.1, 17390721.
6. Hockel M, Knoop C, Schlenger K, Vorndran B, Baussmann E, Mitze M, Knapstein PG, Vaupel P. Intratumoral pO2 predicts survival in advanced cancer of the uterine cervix. Radiother Oncol 1993, 26:45-50. 10.1016/0167-8140(93)90025-4, 8438086.
7. Hockel M, Schlenger K, Aral B, Mitze M, Schaffer U, Vaupel P. Association between tumor hypoxia and malignant progression in advanced cancer of the uterine cervix. Cancer Res 1996, 56:4509-4515.
8. Fyles A, Milosevic M, Hedley D, Pintilie M, Levin W, Manchul L, Hill RP. Tumor hypoxia has independent predictor impact only in patients with node-negative cervix cancer. J Clin Oncol 2002, 20:680-687. 10.1200/JCO.20.3.680, 11821448.
9. Knocke TH, Weitmann HD, Feldmann HJ, Selzer E, Potter R. Intratumoral pO2-measurements as predictive assay in the treatment of carcinoma of the uterine cervix. Radiother Oncol 1999, 53:99-104. 10.1016/S0167-8140(99)00139-5, 10665785.
10. Lyng H, Sundfor K, Trope C, Rofstad EK. Disease control of uterine cervical cancer: relationships to tumor oxygen tension, vascular density, cell density, and frequency of mitosis and apoptosis measured before treatment and during radiotherapy. Clin Cancer Res 2000, 6:1104-1112.
11. Nordsmark M, Bentzen SM, Rudat V, Brizel D, Lartigau E, Stadler P, Becker A, Adam M, Molls M, Dunst J, et al. Prognostic value of tumor oxygenation in 397 head and neck tumors after primary radiation therapy. An international multi-center study. Radiother Oncol 2005, 77:18-24. 10.1016/j.radonc.2005.06.038, 16098619.
12. Chan N, Bristow RG. " Contextual" synthetic lethality and/or loss of heterozygosity: tumor hypoxia and modification of DNA repair. Clin Cancer Res 2010, 16:4553-4560. 10.1158/1078-0432.CCR-10-0527, 20823145.
13. Vaupel P. The role of hypoxia-induced factors in tumor progression. Oncologist 2004, 9(Suppl 5):10-17.
14. Bristow RG, Hill RP. Hypoxia and metabolism. Hypoxia, DNA repair and genetic instability. Nat Rev Cancer 2008, 8:180-192. 10.1038/nrc2344, 18273037.
15. Rofstad EK, Galappathi K, Mathiesen B, Ruud EB. Fluctuating and diffusion-limited hypoxia in hypoxia-induced metastasis. Clin Cancer Res 2007, 13:1971-1978. 10.1158/1078-0432.CCR-06-1967, 17360973.
16. Hoogsteen IJ, Marres HA, van der Kogel AJ, Kaanders JH. The hypoxic tumour microenvironment, patient selection and hypoxia-modifying treatments. Clin Oncol (R Coll Radiol) 2007, 19:385-396. 10.1016/j.clon.2007.03.001, 17433637.
17. Papandreou I, Powell A, Lim AL, Denko N. Cellular reaction to hypoxia: sensing and responding to an adverse environment. Mutat Res 2005, 569:87-100. 10.1016/j.mrfmmm.2004.06.054, 15603754.
18. Bencokova Z, Kaufmann MR, Pires IM, Lecane PS, Giaccia AJ, Hammond EM. ATM activation and signaling under hypoxic conditions. Mol Cell Biol 2009, 29:526-537. 10.1128/MCB.01301-08, 2612523, 18981219.
19. Freiberg RA, Hammond EM, Dorie MJ, Welford SM, Giaccia AJ. DNA damage during reoxygenation elicits a Chk2-dependent checkpoint response. Mol Cell Biol 2006, 26:1598-1609. 10.1128/MCB.26.5.1598-1609.2006, 1430245, 16478982.
20. Gibson SL, Bindra RS, Glazer PM. CHK2-dependent phosphorylation of BRCA1 in hypoxia. Radiat Res 2006, 166:646-651. 10.1667/RR0660.1, 17007555.
21. Olcina M, Lecane PS, Hammond EM. Targeting hypoxic cells through the DNA damage response. Clin Cancer Res 2010, 16:5624-5629. 10.1158/1078-0432.CCR-10-0286, 3000384, 20876254.
22. Pires IM, Bencokova Z, McGurk C, Hammond EM. Exposure to acute hypoxia induces a transient DNA damage response which includes Chk1 and TLK1. Cell Cycle 2010, 9:2502-2507. 3040847, 20581459.
23. Subarsky P, Hill RP. The hypoxic tumour microenvironment and metastatic progression. Clin Exp Metastasis 2003, 20:237-250. 10.1023/A:1022939318102, 12741682.
24. Sullivan R, Graham CH. Hypoxia-driven selection of the metastatic phenotype. Cancer Metastasis Rev 2007, 26:319-331. 10.1007/s10555-007-9062-2, 17458507.
25. Chaudary N, Hill RP. Hypoxia and metastasis. Clin Cancer Res 2007, 13:1947-1949. 10.1158/1078-0432.CCR-06-2971, 17404073.
26. Spiro IJ, Rice GC, Durand RE, Stickler R, Ling CC. Cell killing, radiosensitization and cell cycle redistribution induced by chronic hypoxia. Int J Radiat Oncol Biol Phys 1984, 10:1275-1280. 10.1016/0360-3016(84)90332-8, 6469750.
27. Murray D, Meyn RE, Vanankeren SC. Variations in the spectrum of lesions produced in the DNA of cells from mouse tissues after exposure to gamma-rays in air-breathing or in artificially anoxic animals. Int J Radiat Biol Relat Stud Phys Chem Med 1988, 53:921-933. 10.1080/09553008814551291, 3259562.
28. Zhang H, Koch CJ, Wallen CA, Wheeler KT. Radiation-induced DNA damage in tumors and normal tissues. III. Oxygen dependence of the formation of strand breaks and DNA-protein crosslinks. Radiat Res 1995, 142:163-168. 10.2307/3579024, 7724730.
29. Chan N, Milosevic M, Bristow RG. Tumor hypoxia, DNA repair and prostate cancer progression: new targets and new therapies. Future Oncol 2007, 3:329-341. 10.2217/14796694.3.3.329, 17547528.
30. Overgaard J. Hypoxic radiosensitization: adored and ignored. J Clin Oncol 2007, 25:4066-4074. 10.1200/JCO.2007.12.7878, 17827455.
31. Semenza GL. Hypoxia-inducible factors in physiology and medicine. Cell 2012, 148:399-408. 10.1016/j.cell.2012.01.021, 3437543, 22304911.
32. Wilson WR, Hay MP. Targeting hypoxia in cancer therapy. Nat Rev Cancer 2011, 11:393-410. 10.1038/nrc3064, 21606941.
33. Camps C, Buffa FM, Colella S, Moore J, Sotiriou C, Sheldon H, Harris AL, Gleadle JM, Ragoussis J. hsa-miR-210 Is induced by hypoxia and is an independent prognostic factor in breast cancer. Clin Cancer Res 2008, 14:1340-1348. 10.1158/1078-0432.CCR-07-1755, 18316553.
34. Fu L, Wang G, Shevchuk MM, Nanus DM, Gudas LJ. Generation of a mouse model of Von Hippel-Lindau kidney disease leading to renal cancers by expression of a constitutively active mutant of HIF1alpha. Cancer Res 2011, 71:6848-6856. 10.1158/0008-5472.CAN-11-1745, 3214086, 21908555.
35. Yoo YG, Christensen J, Huang LE. HIF-1alpha confers aggressive malignant traits on human tumor cells independent of its canonical transcriptional function. Cancer Res 2011, 71:1244-1252. 10.1158/0008-5472.CAN-10-2360, 3041864, 21303984.
36. Nakada C, Tsukamoto Y, Matsuura K, Nguyen TL, Hijiya N, Uchida T, Sato F, Mimata H, Seto M, Moriyama M. Overexpression of miR-210, a downstream target of HIF1alpha, causes centrosome amplification in renal carcinoma cells. J Pathol 2011, 224:280-288. 10.1002/path.2860, 21465485.
37. Doe MR, Ascano JM, Kaur M, Cole MD. Myc Posttranscriptionally Induces HIF1 Protein and Target Gene Expression in Normal and Cancer Cells. Cancer Res 2012, 72:949-957. 10.1158/0008-5472.CAN-11-2371, 3288382, 22186139.
38. Pires IM, Bencokova Z, Milani M, Folkes LK, Li JL, Stratford MR, Harris AL, Hammond EM. Effects of acute versus chronic hypoxia on DNA damage responses and genomic instability. Cancer Res 2010, 70:925-935. 10.1158/0008-5472.CAN-09-2715, 2923514, 20103649.
39. Zafarana G, Ishkanian AS, Malloff CA, Locke JA, Sykes J, Thoms J, Lam WL, Squire JA, Yoshimoto M, Ramnarine VR, et al. Copy number alterations of c-MYC and PTEN are prognostic factors for relapse after prostate cancer radiotherapy. Cancer 2012, 118:4053-4062. 10.1002/cncr.26729, 22281794.
40. Huang LE, Bindra RS, Glazer PM, Harris AL. Hypoxia-induced genetic instability-a calculated mechanism underlying tumor progression. J Mol Med 2007, 85:139-148. 10.1007/s00109-006-0133-6, 17180667.
41. Hammond EM, Dorie MJ, Giaccia AJ. ATR/ATM targets are phosphorylated by ATR in response to hypoxia and ATM in response to reoxygenation. J Biol Chem 2003, 278:12207-12213. 10.1074/jbc.M212360200, 12519769.
42. Hsieh CH, Shyu WC, Chiang CY, Kuo JW, Shen WC, Liu RS. NADPH oxidase subunit 4-mediated reactive oxygen species contribute to cycling hypoxia-promoted tumor progression in glioblastoma multiforme. PLoS One 2011, 6:e23945. 10.1371/journal.pone.0023945, 3174133, 21935366.
43. O" Driscoll M, Jeggo PA. The role of double-strand break repair - insights from human genetics. Nat Rev Genet 2006, 7:45-54.
44. Shimada M, Nakanishi M. DNA damage checkpoints and cancer. J Mol Histol 2006, 37:253-260. 10.1007/s10735-006-9039-4, 16841236.
45. Li L, Zou L. Sensing, signaling, and responding to DNA damage: organization of the checkpoint pathways in mammalian cells. J Cell Biochem 2005, 94:298-306. 10.1002/jcb.20355, 15578575.
46. Hammond EM, Denko NC, Dorie MJ, Abraham RT, Giaccia AJ. Hypoxia links ATR and p53 through replication arrest. Mol Cell Biol 2002, 22:1834-1843. 10.1128/MCB.22.6.1834-1843.2002, 135616, 11865061.
47. Gibson SL, Bindra RS, Glazer PM. Hypoxia-induced phosphorylation of Chk2 in an ataxia telangiectasia mutated-dependent manner. Cancer Res 2005, 65:10734-10741. 10.1158/0008-5472.CAN-05-1160, 16322218.
48. Freiberg RA, Krieg AJ, Giaccia AJ, Hammond EM. Checking in on hypoxia/reoxygenation. Cell Cycle 2006, 5:1304-1307. 10.4161/cc.5.12.2811, 16760660.
49. Bouquet F, Ousset M, Biard D, Fallone F, Dauvillier S, Frit P, Salles B, Muller C. A DNA-dependent stress response involving DNA-PK occurs in hypoxic cells and contributes to cellular adaptation to hypoxia. J Cell Sci 2011, 124:1943-1951. 10.1242/jcs.078030, 21576354.
50. Harding SM, Coackley C, Bristow RG. ATM-dependent phosphorylation of 53BP1 in response to genomic stress in oxic and hypoxic cells. Radiother Oncol 2011, 99:307-312. 10.1016/j.radonc.2011.05.039, 21680038.
51. Kim BM, Choi JY, Kim YJ, Woo HD, Chung HW. Reoxygenation following hypoxia activates DNA-damage checkpoint signaling pathways that suppress cell-cycle progression in cultured human lymphocytes. FEBS Lett 2007, 581:3005-3012. 10.1016/j.febslet.2007.05.053, 17544403.
52. Gardner LB, Li Q, Park MS, Flanagan WM, Semenza GL, Dang CV. Hypoxia inhibits G1/S transition through regulation of p27 expression. J Biol Chem 2001, 276:7919-7926. 10.1074/jbc.M010189200, 11112789.
53. Gardner LB, Li F, Yang X, Dang CV. Anoxic fibroblasts activate a replication checkpoint that is bypassed by E1a. Mol Cell Biol 2003, 23:9032-9045. 10.1128/MCB.23.24.9032-9045.2003, 309642, 14645516.
54. Wang L, Gao J, Dai W, Lu L. Activation of Polo-like kinase 3 by hypoxic stresses. J Biol Chem 2008, 283:25928-25935. 10.1074/jbc.M801326200, 2533803, 18650425.
55. Tan C, Zhang LY, Chen H, Xiao L, Liu XP, Zhang JX. Overexpression of the human ubiquitin E3 ligase CUL4A alleviates hypoxia-reoxygenation injury in pheochromocytoma (PC12) cells. Biochem Biophys Res Commun 2011, 416:403-408. 10.1016/j.bbrc.2011.11.054, 22120631.
56. Chan N, Koritzinsky M, Zhao H, Bindra R, Glazer PM, Powell S, Belmaaza A, Wouters B, Bristow RG. Chronic hypoxia decreases synthesis of homologous recombination proteins to offset chemoresistance and radioresistance. Cancer Res 2008, 68:605-614. 10.1158/0008-5472.CAN-07-5472, 18199558.
57. Hubbi ME, Kshitiz, Gilkes DM, Rey S, Wong CC, Luo W, Kim DH, Dang CV, Levchenko A, Semenza GL. A nontranscriptional role for HIF-1alpha as a direct inhibitor of DNA replication. Sci Signal 2013, 6:ra10. 10.1126/scisignal.2003417, 23405012.
58. Hubbi ME, Luo W, Baek JH, Semenza GL. MCM proteins are negative regulators of hypoxia-inducible factor 1. Mol Cell 2011, 42:700-712. 10.1016/j.molcel.2011.03.029, 3131976, 21658608.
59. Papp-Szabo E, Josephy PD, Coomber BL. Microenvironmental influences on mutagenesis in mammary epithelial cells. Int J Cancer 2005, 116:679-685. 10.1002/ijc.21088, 15849743.
60. Keysar SB, Trncic N, Larue SM, Fox MH. Hypoxia/reoxygenation-induced mutations in mammalian cells detected by the flow cytometry mutation assay and characterized by mutant spectrum. Radiat Res 2010, 173:21-26. 10.1667/RR1838.1, 2848454, 20041756.
61. Reynolds TY, Rockwell S, Glazer PM. Genetic instability induced by the tumor microenvironment. Cancer Res 1996, 56:5754-5757.
62. Li CY, Little JB, Hu K, Zhang W, Zhang L, Dewhirst MW, Huang Q. Persistent genetic instability in cancer cells induced by non-DNA-damaging stress exposures. Cancer Res 2001, 61:428-432.
63. Michor F, Iwasa Y, Vogelstein B, Lengauer C, Nowak MA. Can chromosomal instability initiate tumorigenesis?. Semin Cancer Biol 2005, 15:43-49. 10.1016/j.semcancer.2004.09.007, 15613287.
64. Geiersbach KB, Samowitz WS. Microsatellite instability and colorectal cancer. Arch Pathol Lab Med 2011, 135:1269-1277. 10.5858/arpa.2011-0035-RA, 21970482.
65. Shahrzad S, Quayle L, Stone C, Plumb C, Shirasawa S, Rak JW, Coomber BL. Ischemia-induced K-ras mutations in human colorectal cancer cells: role of microenvironmental regulation of MSH2 expression. Cancer Res 2005, 65:8134-8141. 10.1158/0008-5472.CAN-05-0713, 16166287.
66. Edwards RA, Witherspoon M, Wang K, Afrasiabi K, Pham T, Birnbaumer L, Lipkin SM. Epigenetic repression of DNA mismatch repair by inflammation and hypoxia in inflammatory bowel disease-associated colorectal cancer. Cancer Res 2009, 69:6423-6429. 10.1158/0008-5472.CAN-09-1285, 2748849, 19638594.
67. Kondo A, Safaei R, Mishima M, Niedner H, Lin X, Howell SB. Hypoxia-induced enrichment and mutagenesis of cells that have lost DNA mismatch repair. Cancer Res 2001, 61:7603-7607.
68. Furlan D, Sahnane N, Carnevali I, Cerutti R, Bertoni F, Kwee I, Uccella S, Bertolini V, Chiaravalli AM, Capella C. Up-regulation of the hypoxia-inducible factor-1 transcriptional pathway in colorectal carcinomas. Hum Pathol 2008, 39:1483-1494. 10.1016/j.humpath.2008.02.013, 18619649.
69. Lehtonen HJ, Makinen MJ, Kiuru M, Laiho P, Herva R, van Minderhout I, Hogendoorn PC, Cornelisse C, Devilee P, Launonen V, Aaltonen LA. Increased HIF1 alpha in SDH and FH deficient tumors does not cause microsatellite instability. Int J Cancer 2007, 121:1386-1389. 10.1002/ijc.22819, 17520677.
70. Rice GC, Hoy C, Schimke RT. Transient hypoxia enhances the frequency of dihydrofolate reductase gene amplification in Chinese hamster ovary cells. Proc Natl Acad Sci U S A 1986, 83:5978-5982. 10.1073/pnas.83.16.5978, 386420, 3461470.
71. Young SD, Marshall RS, Hill RP. Hypoxia induces DNA overreplication and enhances metastatic potential of murine tumor cells. Proc Natl Acad Sci U S A 1988, 85:9533-9537. 10.1073/pnas.85.24.9533, 282788, 3200838.
72. Rofstad EK, Johnsen NM, Lyng H. Hypoxia-induced tetraploidisation of a diploid human melanoma cell line in vitro. Br J Cancer Suppl 1996, 27:S136-S139. 2149977, 8763866.
73. Coquelle A, Toledo F, Stern S, Bieth A, Debatisse M. A new role for hypoxia in tumor progression: induction of fragile site triggering genomic rearrangements and formation of complex DMs and HSRs. Mol Cell 1998, 2:259-265. 10.1016/S1097-2765(00)80137-9, 9734364.
74. Yuan J, Narayanan L, Rockwell S, Glazer PM. Diminished DNA repair and elevated mutagenesis in mammalian cells exposed to hypoxia and low pH. Cancer Res 2000, 60:4372-4376.
75. Coquelle A, Rozier L, Dutrillaux B, Debatisse M. Induction of multiple double-strand breaks within an hsr by meganucleaseI-SceI expression or fragile site activation leads to formation of double minutes and other chromosomal rearrangements. Oncogene 2002, 21:7671-7679. 10.1038/sj.onc.1205880, 12400009.
76. Mihaylova VT, Bindra RS, Yuan J, Campisi D, Narayanan L, Jensen R, Giordano F, Johnson RS, Rockwell S, Glazer PM. Decreased expression of the DNA mismatch repair gene Mlh1 under hypoxic stress in mammalian cells. Mol Cell Biol 2003, 23:3265-3273. 10.1128/MCB.23.9.3265-3273.2003, 153206, 12697826.
77. Banath JP, Sinnott L, Larrivee B, MacPhail SH, Olive PL. Growth of V79 cells as xenograft tumors promotes multicellular resistance but does not increase spontaneous or radiation-induced mutant frequency. Radiat Res 2005, 164:733-744. 10.1667/3474.1, 16296879.
78. Koshiji M, To KK, Hammer S, Kumamoto K, Harris AL, Modrich P, Huang LE. HIF-1alpha induces genetic instability by transcriptionally downregulating MutSalpha expression. Mol Cell 2005, 17:793-803. 10.1016/j.molcel.2005.02.015, 15780936.
79. Fischer U, Radermacher J, Mayer J, Mehraein Y, Meese E. Tumor hypoxia: impact on gene amplification in glioblastoma. Int J Oncol 2008, 33:509-515.
80. Rodriguez-Jimenez FJ, Moreno-Manzano V, Lucas-Dominguez R, Sanchez-Puelles JM. Hypoxia causes downregulation of mismatch repair system and genomic instability in stem cells. Stem Cells 2008, 26:2052-2062. 10.1634/stemcells.2007-1016, 18511603.
81. Lee JH, Choi IJ, Song DK, Kim DK. Genetic instability in the human lymphocyte exposed to hypoxia. Cancer Genet Cytogenet 2010, 196:83-88. 10.1016/j.cancergencyto.2009.09.002, 19963140.
82. Kumareswaran R, Ludkovski O, Meng A, Sykes J, Pintilie M, Bristow RG. Chronic hypoxia compromises repair of DNA double-strand breaks to drive genetic instability. J Cell Sci 2012, 125:189-199. 10.1242/jcs.092262, 22266907.
83. Mondello C, Smirnova A, Giulotto E. Gene amplification, radiation sensitivity and DNA double-strand breaks. Mutat Res 2010, 704:29-37. 10.1016/j.mrrev.2010.01.008, 20093194.
84. Popp HD, Bohlander SK. Genetic instability in inherited and sporadic leukemias. Genes Chromosomes Cancer 2010, 49:1071-1081. 10.1002/gcc.20823, 20842730.
85. Patel KJ, Yu VP, Lee H, Corcoran A, Thistlethwaite FC, Evans MJ, Colledge WH, Friedman LS, Ponder BA, Venkitaraman AR. Involvement of Brca2 in DNA repair. Mol Cell 1998, 1:347-357. 10.1016/S1097-2765(00)80035-0, 9660919.
86. Yu VP, Koehler M, Steinlein C, Schmid M, Hanakahi LA, van Gool AJ, West SC, Venkitaraman AR. Gross chromosomal rearrangements and genetic exchange between nonhomologous chromosomes following BRCA2 inactivation. Genes Dev 2000, 14:1400-1406. 316655, 10837032.
87. Venkitaraman AR. Linking the cellular functions of BRCA genes to cancer pathogenesis and treatment. Annu Rev Pathol 2009, 4:461-487. 10.1146/annurev.pathol.3.121806.151422, 18954285.
88. Walsh CS, Ogawa S, Scoles DR, Miller CW, Kawamata N, Narod SA, Koeffler HP, Karlan BY. Genome-wide loss of heterozygosity and uniparental disomy in BRCA1/2-associated ovarian carcinomas. Clin Cancer Res 2008, 14:7645-7651. 10.1158/1078-0432.CCR-08-1291, 2677417, 19047089.
89. Min J, Choi ES, Hwang K, Kim J, Sampath S, Venkitaraman AR, Lee H. The Breast Cancer Susceptibility Gene BRCA2 Is Required for the Maintenance of Telomere Homeostasis. J Biol Chem 2012, 287:5091-5101. 10.1074/jbc.M111.278994, 3281639, 22187435.
90. Johnson AB, Barton MC. Hypoxia-induced and stress-specific changes in chromatin structure and function. Mutat Res 2007, 618:149-162. 10.1016/j.mrfmmm.2006.10.007, 1924842, 17292925.
91. Arlt MF, Durkin SG, Ragland RL, Glover TW. Common fragile sites as targets for chromosome rearrangements. DNA Repair (Amst) 2006, 5:1126-1135. 10.1016/j.dnarep.2006.05.010, 16807141.
92. Schwartz M, Zlotorynski E, Goldberg M, Ozeri E, Rahat A, le Sage C, Chen BP, Chen DJ, Agami R, Kerem B. Homologous recombination and nonhomologous end-joining repair pathways regulate fragile site stability. Genes Dev 2005, 19:2715-2726. 10.1101/gad.340905, 1283964, 16291645.
93. Ozeri-Galai E, Schwartz M, Rahat A, Kerem B. Interplay between ATM and ATR in the regulation of common fragile site stability. Oncogene 2008, 27:2109-2117. 10.1038/sj.onc.1210849, 17934520.
94. Tanaka H, Yao MC. Palindromic gene amplification-an evolutionarily conserved role for DNA inverted repeats in the genome. Nat Rev Cancer 2009, 9:216-224. 10.1038/nrc2591, 19212324.
95. Wilson DM, Thompson LH. Molecular mechanisms of sister-chromatid exchange. Mutat Res 2007, 616:11-23. 10.1016/j.mrfmmm.2006.11.017, 17157333.
96. Avidor-Reiss T, Gopalakrishnan J. Building a centriole. Curr Opin Cell Biol 2013, 25:72-77. 10.1016/j.ceb.2012.10.016, 23199753.
97. Chan JY. A clinical overview of centrosome amplification in human cancers. Int J Biol Sci 2011, 7:1122-1144. 3204404, 22043171.
98. Duijf PH, Benezra R. The cancer biology of whole-chromosome instability. Oncogene 2013, 32:4727-4736. 10.1038/onc.2012.616, 23318433.
99. Moser SC, Bensaddek D, Ortmann B, Maure JF, Mudie S, Blow JJ, Lamond AI, Swedlow JR, Rocha S. PHD1 Links Cell-Cycle Progression to Oxygen Sensing through Hydroxylation of the Centrosomal Protein Cep192. Dev Cell 2013, 26:381-392. 10.1016/j.devcel.2013.06.014, 3757158, 23932902.
100. Bristow RG, Ozcelik H, Jalali F, Chan N, Vesprini D. Homologous recombination and prostate cancer: a model for novel DNA repair targets and therapies. Radiother Oncol 2007, 83:220-230. 10.1016/j.radonc.2007.04.016, 17531338.
101. Meng AX, Jalali F, Cuddihy A, Chan N, Bindra RS, Glazer PM, Bristow RG. Hypoxia down-regulates DNA double strand break repair gene expression in prostate cancer cells. Radiother Oncol 2005, 76:168-176. 10.1016/j.radonc.2005.06.025, 16026872.
102. Koshiji M, Kageyama Y, Pete EA, Horikawa I, Barrett JC, Huang LE. HIF-1alpha induces cell cycle arrest by functionally counteracting Myc. EMBO J 2004, 23:1949-1956. 10.1038/sj.emboj.7600196, 404317, 15071503.
103. To KK, Sedelnikova OA, Samons M, Bonner WM, Huang LE. The phosphorylation status of PAS-B distinguishes HIF-1alpha from HIF-2alpha in NBS1 repression. EMBO J 2006, 25:4784-4794. 10.1038/sj.emboj.7601369, 1618093, 17024177.
104. Hayashi M, Yoo YY, Christensen J, Huang LE. Requirement of evading apoptosis for HIF-1alpha-induced malignant progression in mouse cells. Cell Cycle 2011, 10:2364-2372. 10.4161/cc.10.14.16313, 3322472, 21654209.
105. Bindra RS, Schaffer PJ, Meng A, Woo J, Maseide K, Roth ME, Lizardi P, Hedley DW, Bristow RG, Glazer PM. Down-regulation of Rad51 and decreased homologous recombination in hypoxic cancer cells. Mol Cell Biol 2004, 24:8504-8518. 10.1128/MCB.24.19.8504-8518.2004, 516750, 15367671.
106. Bindra RS, Schaffer PJ, Meng A, Woo J, Maseide K, Roth ME, Lizardi P, Hedley DW, Bristow RG, Glazer PM. Alterations in DNA repair gene expression under hypoxia: elucidating the mechanisms of hypoxia-induced genetic instability. Ann N Y Acad Sci 2005, 1059:184-195. 10.1196/annals.1339.049, 16382054.
107. Bindra RS, Glazer PM. Co-repression of mismatch repair gene expression by hypoxia in cancer cells: role of the Myc/Max network. Cancer Lett 2007, 252:93-103. 10.1016/j.canlet.2006.12.011, 17275176.
108. Chan N, Pires IM, Bencokova Z, Coackley C, Luoto KR, Bhogal N, Lakshman M, Gottipati P, Oliver FJ, Helleday T, et al. Contextual synthetic lethality of cancer cell kill based on the tumor microenvironment. Cancer Res 2010, 70:8045-8054. 10.1158/0008-5472.CAN-10-2352, 2978949, 20924112.
109. Wouters BG, Koritzinsky M. Hypoxia signalling through mTOR and the unfolded protein response in cancer. Nat Rev Cancer 2008, 8:851-864. 10.1038/nrc2501, 18846101.
110. Lu Y, Chu A, Turker MS, Glazer PM. Hypoxia-Induced Epigenetic Regulation and Silencing of the BRCA1 Promoter. Mol Cell Biol 2011, 31:3339-3350. 10.1128/MCB.01121-10, 3147797, 21670155.
111. Crosby ME, Kulshreshtha R, Ivan M, Glazer PM. MicroRNA regulation of DNA repair gene expression in hypoxic stress. Cancer Res 2009, 69:1221-1229. 10.1158/0008-5472.CAN-08-2516, 2997438, 19141645.
112. Chang CJ, Yang JY, Xia W, Chen CT, Xie X, Chao CH, Woodward WA, Hsu JM, Hortobagyi GN, Hung MC. EZH2 promotes expansion of breast tumor initiating cells through activation of RAF1-beta-catenin signaling. Cancer Cell 2011, 19:86-100. 10.1016/j.ccr.2010.10.035, 3041516, 21215703.
113. Cao P, Deng Z, Wan M, Huang W, Cramer SD, Xu J, Lei M, Sui G. MicroRNA-101 negatively regulates Ezh2 and its expression is modulated by androgen receptor and HIF-1alpha/HIF-1beta. Mol Cancer 2010, 9:108. 10.1186/1476-4598-9-108, 2881117, 20478051.
114. Tsuchimoto T, Sakata K, Someya M, Yamamoto H, Hirayama R, Matsumoto Y, Furusawa Y, Hareyama M. Gene expression associated with DNA-dependent protein kinase activity under normoxia, hypoxia, and reoxygenation. J Radiat Res 2011, 52:464-471. 10.1269/jrr.10137, 21905307.
115. Wirthner R, Wrann S, Balamurugan K, Wenger RH, Stiehl DP. Impaired DNA double-strand break repair contributes to chemoresistance in HIF-1 alpha-deficient mouse embryonic fibroblasts. Carcinogenesis 2008, 29:2306-2316. 10.1093/carcin/bgn231, 18842680.
116. Lara PC, Lloret M, Clavo B, Apolinario RM, Bordon E, Rey A, Falcon O, Alonso AR, Belka C. Hypoxia downregulates Ku70/80 expression in cervical carcinoma tumors. Radiother Oncol 2008, 89:222-226. 10.1016/j.radonc.2008.07.018, 18706726.
117. He F, Li L, Kim D, Wen B, Deng X, Gutin PH, Ling CC, Li GC. Adenovirus-mediated expression of a dominant negative Ku70 fragment radiosensitizes human tumor cells under aerobic and hypoxic conditions. Cancer Res 2007, 67:634-642. 10.1158/0008-5472.CAN-06-1860, 17234773.
118. Sprong D, Janssen HL, Vens C, Begg AC. Resistance of hypoxic cells to ionizing radiation is influenced by homologous recombination status. Int J Radiat Oncol Biol Phys 2006, 64:562-572. 10.1016/j.ijrobp.2005.09.031, 16343804.
119. Bindra RS, Gibson SL, Meng A, Westermark U, Jasin M, Pierce AJ, Bristow RG, Classon MK, Glazer PM. Hypoxia-induced down-regulation of BRCA1 expression by E2Fs. Cancer Res 2005, 65:11597-11604. 10.1158/0008-5472.CAN-05-2119, 16357170.
120. Madan E, Gogna R, Pati U. p53Ser15 Phosphorylation disrupts p53-RPA70 complex and induces RPA70-mediated DNA repair in hypoxia. Biochem J 2012, 443:811-820. 10.1042/BJ20111627, 22288499.
121. Hoffelder DR, Luo L, Burke NA, Watkins SC, Gollin SM, Saunders WS. Resolution of anaphase bridges in cancer cells. Chromosoma 2004, 112:389-397.
122. Wimmer K, Etzler J. Constitutional mismatch repair-deficiency syndrome: have we so far seen only the tip of an iceberg?. Hum Genet 2008, 124:105-122. 10.1007/s00439-008-0542-4, 18709565.
123. Li J, Koike J, Kugoh H, Arita M, Ohhira T, Kikuchi Y, Funahashi K, Takamatsu K, Boland CR, Koi M, Hemmi H. Down-regulation of MutS homolog 3 by hypoxia in human colorectal cancer. Biochim Biophys Acta 2012, 1823:889-899. 10.1016/j.bbamcr.2012.01.017, 3793328, 22343000.
124. Grandori C, Cowley SM, James LP, Eisenman RN. The Myc/Max/Mad network and the transcriptional control of cell behavior. Annu Rev Cell Dev Biol 2000, 16:653-699. 10.1146/annurev.cellbio.16.1.653, 11031250.
125. Nakamura H, Tanimoto K, Hiyama K, Yunokawa M, Kawamoto T, Kato Y, Yoshiga K, Poellinger L, Hiyama E, Nishiyama M. Human mismatch repair gene, MLH1, is transcriptionally repressed by the hypoxia-inducible transcription factors, DEC1 and DEC2. Oncogene 2008, 27:4200-4209. 10.1038/onc.2008.58, 18345027.
126. Nouspikel T. DNA repair in mammalian cells : Nucleotide excision repair: variations on versatility. Cell Mol Life Sci 2009, 66:994-1009. 10.1007/s00018-009-8737-y, 19153657.
127. Rezvani HR, Mahfouf W, Ali N, Chemin C, Ged C, Kim AL, de Verneuil H, Taieb A, Bickers DR, Mazurier F. Hypoxia-inducible factor-1alpha regulates the expression of nucleotide excision repair proteins in keratinocytes. Nucleic Acids Res 2010, 38:797-809. 10.1093/nar/gkp1072, 2817476, 19934262.
128. Filippi S, Latini P, Frontini M, Palitti F, Egly JM, Proietti-De-Santis L. CSB protein is (a direct target of HIF-1 and) a critical mediator of the hypoxic response. EMBO J 2008, 27:2545-2556. 10.1038/emboj.2008.180, 2567410, 18784753.
129. Kitao H, Takata M. Fanconi anemia: a disorder defective in the DNA damage response. Int J Hematol 2011, 93:417-424. 10.1007/s12185-011-0777-z, 21331524.
130. Kuhnert VM, Kachnic LA, Li L, Purschke M, Gheorghiu L, Lee R, Held KD, Willers H. FANCD2-deficient human fibroblasts are hypersensitive to ionising radiation at oxygen concentrations of 0% and 3% but not under normoxic conditions. Int J Radiat Biol 2009, 85:523-531. 10.1080/09553000902883810, 3758881, 19466639.
131. Ramaekers CH, van den Beucken T, Meng A, Kassam S, Thoms J, Bristow RG, Wouters BG. Hypoxia disrupts the Fanconi anemia pathway and sensitizes cells to chemotherapy through regulation of UBE2T. Radiother Oncol 2011, 101:190-197. 10.1016/j.radonc.2011.05.059, 21722982.
132. Sun JD, Liu Q, Wang J, Ahluwalia D, Ferraro D, Wang Y, Duan JX, Ammons WS, Curd JG, Matteucci MD, Hart CP. Selective tumor hypoxia targeting by hypoxia-activated prodrug TH-302 inhibits tumor growth in preclinical models of cancer. Clin Cancer Res 2012, 18:758-770. 10.1158/1078-0432.CCR-11-1980, 22184053.
133. van den Beucken T, Magagnin MG, Jutten B, Seigneuric R, Lambin P, Koritzinsky M, Wouters BG. Translational control is a major contributor to hypoxia induced gene expression. Radiother Oncol 2011, 99:379-384. 10.1016/j.radonc.2011.05.058, 21719133.
134. Zhao H, Luoto KR, Meng AX, Bristow RG. The receptor tyrosine kinase inhibitor amuvatinib (MP470) sensitizes tumor cells to radio- and chemo-therapies in part by inhibiting homologous recombination. Radiother Oncol 2011, 101:59-65. 10.1016/j.radonc.2011.08.013, 21903282.
135. Matsumoto S, Batra S, Saito K, Yasui H, Choudhuri R, Gadisetti C, Subramanian S, Devasahayam N, Munasinghe JP, Mitchell JB, Krishna MC. Antiangiogenic agent sunitinib transiently increases tumor oxygenation and suppresses cycling hypoxia. Cancer Res 2011, 71:6350-6359. 10.1158/0008-5472.CAN-11-2025, 3196374, 21878530.
136. Kaelin WG. The concept of synthetic lethality in the context of anticancer therapy. Nat Rev Cancer 2005, 5:689-698. 10.1038/nrc1691, 16110319.
137. Chalmers AJ, Lakshman M, Chan N, Bristow RG. Poly(ADP-ribose) polymerase inhibition as a model for synthetic lethality in developing radiation oncology targets. Semin Radiat Oncol 2010, 20:274-281. 10.1016/j.semradonc.2010.06.001, 20832020.
138. Hegan DC, Lu Y, Stachelek GC, Crosby ME, Bindra RS, Glazer PM. Inhibition of poly(ADP-ribose) polymerase down-regulates BRCA1 and RAD51 in a pathway mediated by E2F4 and p130. Proc Natl Acad Sci U S A 2010, 107:2201-2206. 10.1073/pnas.0904783107, 2836641, 20133863.
139. Rajesh C, Baker DK, Pierce AJ, Pittman DL. The splicing-factor related protein SFPQ/PSF interacts with RAD51D and is necessary for homology-directed repair and sister chromatid cohesion. Nucleic Acids Res 2011, 39:132-145. 10.1093/nar/gkq738, 3017596, 20813759.
140. Feng Z, Scott SP, Bussen W, Sharma GG, Guo G, Pandita TK, Powell SN. Rad52 inactivation is synthetically lethal with BRCA2 deficiency. Proc Natl Acad Sci U S A 2011, 108:686-691. 10.1073/pnas.1010959107, 3021033, 21148102.
141. McEllin B, Camacho CV, Mukherjee B, Hahm B, Tomimatsu N, Bachoo RM, Burma S. PTEN loss compromises homologous recombination repair in astrocytes: implications for glioblastoma therapy with temozolomide or poly(ADP-ribose) polymerase inhibitors. Cancer Res 2010, 70:5457-5464. 10.1158/0008-5472.CAN-09-4295, 2896430, 20530668.
142. Fraser M, Zhao H, Luoto KR, Lundin C, Coackley C, Chan N, Joshua AM, Bismar TA, Evans A, Helleday T, Bristow RG. PTEN deletion in prostate cancer cells does not associate with loss of RAD51 function: implications for radiotherapy and chemotherapy. Clin Cancer Res 2012, 18:1015-1027. 10.1158/1078-0432.CCR-11-2189, 3378487, 22114138.
143. Martin SA, McCabe N, Mullarkey M, Cummins R, Burgess DJ, Nakabeppu Y, Oka S, Kay E, Lord CJ, Ashworth A. DNA polymerases as potential therapeutic targets for cancers deficient in the DNA mismatch repair proteins MSH2 or MLH1. Cancer Cell 2010, 17:235-248. 10.1016/j.ccr.2009.12.046, 2845806, 20227038.
144. Martin SA, Hewish M, Sims D, Lord CJ, Ashworth A. Parallel high-throughput RNA interference screens identify PINK1 as a potential therapeutic target for the treatment of DNA mismatch repair-deficient cancers. Cancer Res 2011, 71:1836-1848. 10.1158/0008-5472.CAN-10-2836, 21242281.